Abstract
Protein tyrosine phosphatases (PTPs) are a diverse family of enzymes encoded by 107 genes in the human genome. Together with protein tyrosine kinases (PTKs), PTPs regulate various cellular activities essential for the initiation and maintenance of malignant phenotypes. While PTK inhibitors are now used routinely for cancer treatment, the PTP inhibitor development field is still in the discovery phase. In this article, the suitability of targeting PTPs for novel anticancer drug discovery is discussed. Examples are presented for PTPs that have been targeted for anticancer drug discovery as well as potential new PTP targets for novel anticancer drug discovery.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Animals
-
Anticarcinogenic Agents / chemistry
-
Anticarcinogenic Agents / pharmacology
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Agents / therapeutic use
-
Drug Design*
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / pharmacology*
-
Enzyme Inhibitors / therapeutic use
-
Humans
-
Isoenzymes / antagonists & inhibitors
-
Isoenzymes / chemistry
-
Isoenzymes / metabolism
-
Protein Tyrosine Phosphatase, Non-Receptor Type 11 / antagonists & inhibitors
-
Protein Tyrosine Phosphatase, Non-Receptor Type 11 / chemistry
-
Protein Tyrosine Phosphatase, Non-Receptor Type 11 / metabolism
-
Protein Tyrosine Phosphatases / antagonists & inhibitors*
-
Protein Tyrosine Phosphatases / chemistry
-
Protein Tyrosine Phosphatases / metabolism*
Substances
-
Anticarcinogenic Agents
-
Antineoplastic Agents
-
Enzyme Inhibitors
-
Isoenzymes
-
Protein Tyrosine Phosphatase, Non-Receptor Type 11
-
Protein Tyrosine Phosphatases